[go: up one dir, main page]
Skip to main content

Advertisement

Springer Nature Link
Log in

Using oral ziprasidone effectively: the food effect and dose-response

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Ziprasidone is a newer “atypical” or “secondgeneration” antipsychotic. Oral ziprasidone (zipras idone hydrochlor ide) has been approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (with or without psychotic features). Comparisons with other second-generation antipsychotics in meta-analyses reveal similar efficacy to that observed for quetiapine or aripiprazole, but inferior efficacy to that of olanzapine or risperidone in the treatment of schizophrenia. However, the rate of dose titration and the dose achieved may have an important bearing on ziprasidone’s efficacy profile, with a target dose range of 120-160 mg/day being associated with optimal symptom control and greater persistence with treatment. In addition, enhancing ziprasidone’s effectiveness requires ensuring that ziprasidone is administered with a 500 kcal meal; otherwise, absorption of oral ziprasidone is substantially reduced and cannot be compensated for by increasing the prescribed dose. Regarding tolerability, ziprasidone has important advantages in that it is not associated with clinically significant weight gain or adverse changes in cholesterol, triglycerides, or glycemic control, and patients may experience moderate improvement in these measures when switching to ziprasidone from a different antipsychotic. Ziprasidone also lacks significant persistent effects on prolactin levels, is not anticholinergic, and only infrequently causes extrapyramidal side effects or postural hypotension; however, it can be associated with somnolence. Ziprasidone may prolong the electrocardiogram (ECG) QT interval but this does not appear to pose a substantial clinical problem. Provided that an adequate dose of ziprasidone is prescribed, and administered with a 500 kcal meal, ziprasidone can be effectively used to control symptoms without the long-term liabilities of metabolic side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13:137–177.

    Article  PubMed  CAS  Google Scholar 

  2. Pfizer, Inc. US Geodon (ziprasidone HCl) and Geodon (ziprasidone mesylate) for injection, LAB-0272-3.0 [package insert]. June 2008. Available at: www.pfizer.com/files/products/uspi_geodon.pdf. Accessed June 1, 2009.

  3. Taylor D. Ziprasidone in the management of schizophrenia. CNS Drugs. 2003;17:423–430.

    Article  PubMed  CAS  Google Scholar 

  4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553–564.

    Article  PubMed  CAS  Google Scholar 

  5. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152–163.

    Article  PubMed  Google Scholar 

  6. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917–1928.

    Article  PubMed  CAS  Google Scholar 

  7. Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998;18:9–15.

    PubMed  CAS  Google Scholar 

  8. Miceli JJ, Glue P, Alderman J, Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull. 2007;40:58–68.

    PubMed  Google Scholar 

  9. Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, cross-over trial. J Clin Psychiatry. 2009;70:58–62.

    Article  PubMed  CAS  Google Scholar 

  10. Vreeland B, Toto AM, Sakowitz M. Solutions for Wellness. 3rd edition. Indianapolis, IN: Eli Lilly and Co; 2008.

    Google Scholar 

  11. Chermá MD, Reis M, Hägg S, Ahlner J, Bengtsson F. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. Ther Drug Monit. 2008;30:682–688.

    Article  PubMed  CAS  Google Scholar 

  12. Citrome L, Reist C, Palmer L, et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res. 2009;108:238–244.

    Article  PubMed  Google Scholar 

  13. Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol. 2005;25:388–391.

    Article  PubMed  Google Scholar 

  14. Citrome L, Jaffe A, Levine J. The ups and downs of dosing second-generation antipsychotics. Psychiatr Serv. 2007;58:11.

    Article  PubMed  Google Scholar 

  15. Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J Clin Psychiatry. 2009;70:975–982.

    Article  PubMed  CAS  Google Scholar 

  16. Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in subjects with schizophrenia or bipolar disorder. Poster presentation NR6-105 presented at: 161st Annual Meeting of the American Psychiatric Association; May 3–8, 2008; Washington, DC.

  17. Mullins CD, Shaya FT, Zito JM, Obeidat N, Naradzay J, Harrison DJ. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res. 2006;83:277–284.

    Article  PubMed  Google Scholar 

  18. Joyce AT, Harrison DJ, Loebel AD, Carter CT, Ollendorf DA. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res. 2006;83:285–292.

    Article  PubMed  Google Scholar 

  19. Citrome L, Yang R, Glue P, Karayal ON. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res. 2009;111:39–45.

    Article  PubMed  Google Scholar 

  20. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192–208.

    Article  PubMed  CAS  Google Scholar 

  21. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818–825.

    Article  PubMed  Google Scholar 

  22. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873–883.

    Article  PubMed  CAS  Google Scholar 

  23. Citrome L. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2008;22:69–72.

    Article  CAS  Google Scholar 

  24. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595–600.

    Article  PubMed  CAS  Google Scholar 

  25. Weiden PJ, Simpson GM, Potkin SG, O’sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580–588.

    Article  PubMed  CAS  Google Scholar 

  26. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611–622.

    Article  PubMed  Google Scholar 

  27. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.

    Article  PubMed  CAS  Google Scholar 

  28. Citrome L. The effectiveness criterion: balancing efficacy against the risks of weight gain. J Clin Psychiatry. 2007;68(suppl. 12):12–17.

    Google Scholar 

  29. Weiden PJ, Iqbal N, Mendelowitz AJ, Tandon R, Zimbroff DL, Ross R. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract. 2002;8:81–97.

    Article  PubMed  Google Scholar 

  30. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312:71–72.

    PubMed  CAS  Google Scholar 

  31. Citrome L, Ketter TA. Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. Int J Clin Pract. 2009;63:353–359.

    Article  PubMed  CAS  Google Scholar 

  32. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68:1876–1885.

    Article  PubMed  CAS  Google Scholar 

  33. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61:933–941.

    PubMed  CAS  Google Scholar 

  34. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 2005;178:514–523.

    Article  CAS  Google Scholar 

  35. Daniel DG, Zimbroff DL, Swift RH, Harrigan EP. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004;19:9–15.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, and the Nathan S. Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg, NY, 10962, USA

    Leslie Citrome

Authors
  1. Leslie Citrome
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leslie Citrome.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Citrome, L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Therapy 26, 739–748 (2009). https://doi.org/10.1007/s12325-009-0055-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0055-0

Keywords